Docking studies for melatonin receptors

References

• Mori W, Lerner AB. A microscopic bioassay for melatonin. Endocrinology. 1960;67:443–450.
   PubMed Web of Science ®Google Scholar
• Wright MR, Lerner AB. Action of thyroxine analogues on frog melanocytes. Nature. 1960;185:169–170.
   PubMed Web of Science ®Google Scholar
• Klein DC, Coon SL, Roseboom PH, et al. The melatonin rhythm-generating enzyme: molecular regulation of serotonin N-acetyltransferase in the pineal gland. Recent Prog Horm Res. 1997;52:307–357.
   PubMedGoogle Scholar
• Tosini G, Owino S, Guillaume JL, et al. Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease. Bioessays. 2014;36(8):778–787.
   PubMed Web of Science ®Google Scholar
• Wurtman RJ, Axelrod J, Phillips LS. Melatonin synthesis in the pineal gland: control by light. Science. 1963;142(3595):1071–1073.
   PubMedGoogle Scholar
• Klein DC. Arylalkylamine N-acetyltransferase: “the Timezyme”. J Biol Chem. 2007;282(7):4233–4237.
   PubMed Web of Science ®Google Scholar
• Cazamea-Catalan D, Besseau L, Falcon J, et al. The timing of Timezyme diversification in vertebrates. PLoS One. 2014;9(12):e112380.
   PubMed Web of Science ®Google Scholar
• Rath MF, Coon SL, Amaral FG, et al. Melatonin synthesis: acetylserotonin O-methyltransferase (ASMT) is strongly expressed in a subpopulation of pinealocytes in the male rat pineal gland. Endocrinology. 2016;157(5):2028–2040.
   PubMed Web of Science ®Google Scholar
• Bubenik GA, Brown GM, Uhlir I, et al. Immunohistological localization of N-acetylindolealkylamines in pineal gland, retina and cerebellum. Brain Res. 1974;81(2):233–242.
   PubMed Web of Science ®Google Scholar
• Stefulj J, Hortner M, Ghosh M, et al. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res. 2001;30(4):243–247.
   PubMed Web of Science ®Google Scholar
• Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;n27(2):101–110.
   Google Scholar
• Wess J. Mutational analysis of muscarinic acetylcholine receptors: structural basis of ligand/receptor/G protein interactions. Life Sci. 1993;53(19):1447–1463.
   PubMed Web of Science ®Google Scholar
• Navajas C, Kokkola T, Poso A, et al. A rhodopsin-based model for melatonin recognition at its G protein-coupled receptor. Eur J Pharmacol. 1996;304(1–3):173–183.
   PubMed Web of Science ®Google Scholar
• Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron. 1994;13(5):1177–1185.
   PubMed Web of Science ®Google Scholar
• Reppert SM, Weaver DR, Godson C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol Sci. 1996;17(3):100–112.
   PubMed Web of Science ®Google Scholar
• Slaugenhaupt SA, Roca AL, Liebert CB, et al. Mapping of the gene for the Mel1a-melatonin receptor to human chromosome 4 (MTNR1A) and mouse chromosome 8 (Mtnr1a). Genomics. 1995;27(2):355–367.
   PubMed Web of Science ®Google Scholar
• Reppert SM, Godson C, Mahle CD, et al. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA. 1995;92(19):8734–8738.
   PubMed Web of Science ®Google Scholar
• Nosjean O, Ferro M, Coge F, et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem. 2000;275(40):31311–31317.
   PubMed Web of Science ®Google Scholar
• Vella F, Ferry G, Delagrange P, et al. NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol. 2005;71(1–2):1–12.
   PubMed Web of Science ®Google Scholar
• Cecon E, Oishi A, Jockers R. Melatonin receptors: molecular pharmacology and signalling in the context of system bias. Br J Pharmacol. 2017;174(14):2409–2421.
   PubMedGoogle Scholar
• Reppert SM. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms. 1997;12(6):528–531.
   PubMed Web of Science ®Google Scholar
• von Gall C, Weaver DR, Kock M, et al. Melatonin limits transcriptional impact of phosphoCREB in the mouse SCN via the Mel1a receptor. Neuroreport. 2000;11(9):1803–1807.
   PubMed Web of Science ®Google Scholar
• Rivara S, Lorenzi S, Mor M, et al. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models. J Med Chem. 2005;48(12):4049–4060.
   PubMed Web of Science ®Google Scholar
• Vanecek J. Cellular mechanisms of melatonin action. Physiol Rev. 1998;78(3):687–721.
   PubMed Web of Science ®Google Scholar
• Brydon L, Barrett P, Morgan PJ, et al. Investigation of the human Mel 1a melatonin receptor using anti-receptor antibodies. Adv Exp Med Biol. 1999;460:215–220.
   PubMed Web of Science ®Google Scholar
• Petit L, Guardiola B, Delagrange P, et al. [Signaling by melatonin receptors]. Therapie. 1998;53(5):421–428.
   PubMed Web of Science ®Google Scholar
• Tslm ST, Wong JT, Wong YH. CGP 52608-induced cyst formation in dinoflagellates: possible involvement of a nuclear receptor for melatonin. J Pineal Res. 1996;21(2):101–107.
   PubMed Web of Science ®Google Scholar
• Shiu SY, Pang B, Tam CW, et al. Signal transduction of receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells involves dual activation of Galpha(s) and Galpha(q) proteins. J Pineal Res. 2010;49(3):301–311.
   PubMed Web of Science ®Google Scholar
• Chen J, Chen G, Li J, et al. Melatonin attenuates inflammatory response-induced brain edema in early brain injury following a subarachnoid hemorrhage: a possible role for the regulation of pro-inflammatory cytokines. J Pineal Res. 2014;57(3):340–347.
   PubMed Web of Science ®Google Scholar
• Mody SM, Ho MK, Joshi SA, et al. Incorporation of Galpha(z)-specific sequence at the carboxyl terminus increases the promiscuity of galpha(16) toward G(i)-coupled receptors. Mol Pharmacol. 2000;57(1):13–23.
   PubMed Web of Science ®Google Scholar
• Lai FP, Mody SM, Yung LY, et al. Molecular determinants for the differential coupling of Galpha(16) to the melatonin MT1, MT2 and Xenopus Mel1c receptors. J Neurochem. 2002;80(5):736–745.
   PubMed Web of Science ®Google Scholar
• New DC, Tsim ST, Wong YH. G protein-linked effector and second messenger systems involved in melatonin signal transduction. Neurosignals. 2003;12(2):59–70.
   PubMedGoogle Scholar
• Ahmed R, Mahavadi S, Al-Shboul O, et al. Characterization of signaling pathways coupled to melatonin receptors in gastrointestinal smooth muscle. Regul Pept. 2013;184:96–103.
   PubMedGoogle Scholar
• Lee SJ, Jung YH, Oh SY, et al. Melatonin enhances the human mesenchymal stem cells motility via melatonin receptor 2 coupling with Galphaq in skin wound healing. J Pineal Res. 2014;57(4):393–407.
   PubMed Web of Science ®Google Scholar
• Pala D, Lodola A, Bedini A, et al. Homology models of melatonin receptors: challenges and recent advances. Int J Mol Sci. 2013;14(4):8093–8121.
   PubMed Web of Science ®Google Scholar
• Pala D, Beuming T, Sherman W, et al. Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. J Chem Inf Model. 2013;53(4):821–835.
   PubMed Web of Science ®Google Scholar
• Romera JA, Sánchez-Murcia PA, Alvarez-Builla J, et al. Bases moleculares de la selectividad de ligandos por receptores de melatonina. Dianas. 2013;2:1–8.
   Google Scholar
• Grol CJ, Jansen JM. The high affinity melatonin binding site probed with conformationally restricted ligands–II. Homology modeling of the receptor. Bioorg Med Chem. 1996;4(8):1333–1339.
   PubMed Web of Science ®Google Scholar
• Chugunov AO, Farce A, Chavatte P, et al. Differences in binding sites of two melatonin receptors help to explain their selectivity to some melatonin analogs: a molecular modeling study. J Biomol Struct Dyn. 2006;24(2):91–107.
   PubMed Web of Science ®Google Scholar
• Chugunov AO, Chavatte P. Bioinformatics of genome regulation and structure II. In: Nikolay KRH, editors. Lucia.Novosibirsk, Russia. no Milanesi, editor; 2006.
   Google Scholar
• Halip LRC, Borota A, Bora A. Insight the binding site of human melatonin MTR1A receptor. Rev Roum Chim. 2015;60(2-3):213–218.
   Web of Science ®Google Scholar
• Farce A, Chugunov AO, Loge C, et al. Homology modeling of MT1 and MT2 receptors. Eur J Med Chem. 2008;43(9):1926–1944.
   PubMed Web of Science ®Google Scholar
• Ebisawa T, Karne S, Lerner MR, et al. Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melanophores. Proc Natl Acad Sci U S A. 1994;91(13):6133–6137.
   PubMed Web of Science ®Google Scholar
• Marot C, Chavatte P, Morin-Allory L, et al. Pharmacophoric search and 3D-QSAR comparative molecular field analysis studies on agonists of melatonin sheep receptors. J Med Chem. 1998;41(23):4453–4465.
   PubMed Web of Science ®Google Scholar
• Rivara S, Mor M, Silva C, et al. Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation. J Med Chem. 2003;46(8):1429–1439.
   PubMed Web of Science ®Google Scholar
• Rivara S, Diamantini G, Di Giacomo B, et al. Reassessing the melatonin pharmacophore–enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue. Bioorg Med Chem. 2006;14(10):3383–3391.
   PubMed Web of Science ®Google Scholar
• Mazna P, Obsilova V, Jelinkova I, et al. Molecular modeling of human MT2 melatonin receptor: the role of Val204, Leu272 and Tyr298 in ligand binding. J Neurochem. 2004;91(4):836–842.
   PubMed Web of Science ®Google Scholar
• Mazna P, Berka K, Jelinkova I, et al. Ligand binding to the human MT2 melatonin receptor: the role of residues in transmembrane domains 3, 6, and 7. Biochem Biophys Res Commun. 2005;332(3):726–734.
   PubMed Web of Science ®Google Scholar
• Jacobson KA, Costanzi S. New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors. Mol Pharmacol. 2012;82(3):361–371.
   PubMed Web of Science ®Google Scholar
• Spadoni G, Bedini A, Diamantini G, et al. Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists. ChemMedChem. 2007;2(12):1741–1749.
   PubMed Web of Science ®Google Scholar
• Spadoni G, Bedini A, Lucarini S, et al. Highly potent and selective MT2 melatonin receptor full agonists from conformational analysis of 1-benzyl-2-acylaminomethyl-tetrahydroquinolines. J Med Chem. 2015;58(18):7512–7525.
   PubMed Web of Science ®Google Scholar
• Wan N, Zhang FF, Ju J, et al. Investigational selective melatoninergic ligands for receptor subtype MT2. Mini Rev Med Chem. 2013;13(10):1462–1474.
   PubMed Web of Science ®Google Scholar
• Conway S, Drew JE, Mowat ES, et al. Chimeric melatonin mt1 and melatonin-related receptors. Identification of domains and residues participating in ligand binding and receptor activation of the melatonin mt1 receptor. J Biol Chem. 2000;275(27):20602–20609.
   PubMed Web of Science ®Google Scholar
• Conway S, Canning SJ, Barrett P, et al. The roles of valine 208 and histidine 211 in ligand binding and receptor function of the ovine Mel1a beta melatonin receptor. Biochem Biophys Res Commun. 1997;239:418–423.
   PubMed Web of Science ®Google Scholar
• Kokkola T, Watson MA, White J, et al. Mutagenesis of human Mel1a melatonin receptor expressed in yeast reveals domains important for receptor function. Biochem Biophys Res Commun. 1998;249:531–536.
   PubMed Web of Science ®Google Scholar
• Gubitz AK, Reppert SM. Chimeric and point-mutated receptors reveal that a single glycine residue in transmembrane domain 6 is critical for high affinity melatonin binding. Endocrinology. 2000;141(3):1236–1244.
   PubMed Web of Science ®Google Scholar
• Kokkola T, Foord SM, Watson MA, et al. Important amino acids for the function of the human MT1 melatonin receptor. Biochem Pharmacol. 2003;65:1463–1471.
   PubMed Web of Science ®Google Scholar
• Almaula N, Ebersole BJ, Ballesteros JA, et al. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. Mol Pharmacol. 1996;50:34–42.
   PubMed Web of Science ®Google Scholar
• Wetzel JM, Salon JA, Tamm JA, et al. Modeling and mutagenesis of the human alpha 1a-adrenoceptor: orientation and function of transmembrane helix V sidechains. Recept Channels. 1996;4:165–177.
   PubMedGoogle Scholar
• Conway S, Mowat ES, Drew JE, et al. Serine residues 110 and 114 are required for agonist binding but not antagonist binding to the melatonin MT1 receptor. Biochem Biophys Res Commun. 2001;282:1229–1236.
   PubMed Web of Science ®Google Scholar
• Zuscik MJ, Porter JE, Gaivin R, et al. Identification of a conserved switch residue responsible for selective constitutive activation of the β2-adrenergic receptor. J Biol Chem. 1998;273:3401–3407.
   PubMed Web of Science ®Google Scholar
• Kam KWL, New DC, Wong YH. Constitutive activation of the opioid receptor-like (ORL1) receptor by mutation of Asn133 to tryptophan in the third transmembrane region. J Neurochem. 2002;83:1461–1470.
   PubMed Web of Science ®Google Scholar
• Braden MR, Nichols DE. Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Mol Pharmacol. 2007;72:1200–1209.
   PubMed Web of Science ®Google Scholar
• Pollock NJ, Manelli AM, Hutchins CW, et al. Serine mutations in transmembrane V of the dopamine D1 receptor affect ligand interactions and receptor activation. J Biol Chem. 1992;267:17780–17786.
   PubMed Web of Science ®Google Scholar
• Gerdin MJ, Mseeh F, Dubocovich ML. Mutagenesis studies of the human MT2 melatonin receptor. Biochem Pharmacol. 2003;66:315–320.
   PubMed Web of Science ®Google Scholar
• Zlotos DP, Jockers R, Cecon E, et al. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014;57(8):3161–3185.
   PubMed Web of Science ®Google Scholar
• Campos Costa I, Nogueira Carvalho H, Fernandes L. Aging, circadian rhythms and depressive disorders: a review. Am J Neurodegener Dis. 2013;29:228–246.
   Google Scholar
• Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology (Bethesda). 2014;29(5):325–333.
   PubMed Web of Science ®Google Scholar
• Pintor J, Peláez T, Hoyle CH, et al. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor. Br J Pharmacol. 2003;138(5):831–836.
   PubMed Web of Science ®Google Scholar
• Proietti S, Cucina A, Reiter RJ, et al. Molecular mechanisms of melatonin’s inhibitory actions on breast cancer. Cell Mol Life Sci. 2013;70:2139–2157.
   PubMed Web of Science ®Google Scholar
• Mao L, Dauchy RT, Blask DE, et al. Circadian gating of epithelial-to-mesenchymal transition in breast cancer cells via melatonin-regulation of GSK3. Mol Endocrinol. 2012;26:1808–1820.
   PubMedGoogle Scholar